Abstract
There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists
Mini-Reviews in Medicinal Chemistry
Title: CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Volume: 8 Issue: 11
Author(s): Yan Lavrovsky, Yan A. Ivanenkov, Konstantin V. Balakin, Darya A. Medvedeva and Alexandre V. Ivachtchenko
Affiliation:
Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists
Abstract: There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Export Options
About this article
Cite this article as:
Lavrovsky Yan, Ivanenkov A. Yan, Balakin V. Konstantin, Medvedeva A. Darya and Ivachtchenko V. Alexandre, CXCR4 Receptor as a Promising Target for Oncolytic Drugs, Mini-Reviews in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/138955708785909907
DOI https://dx.doi.org/10.2174/138955708785909907 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Current Medicinal Chemistry 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Functions of S100 Proteins
Current Molecular Medicine Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Growth Retardation of Poorly Transfectable Tumor by Multiple Injections of Plasmids Encoding PE40 Based Targeted Toxin Complexed with Polyethylenimine
Current Gene Therapy Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer
Clinical Cancer Drugs Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design